Analysts have recently taken a positive turn on uniQure N.V. (QURE), assigning the stock an ‘Outperform’ rating with a price target of $35, signaling notable upside potential from its current trading price of $18.26. This recommendation from Mizuho’s Uy Ear, issued on March 11, 2026, indicates growing confidence in the company’s prospects, setting the stage for an intriguing investment opportunity for both institutional and retail investors.
Recent Price Action
In the past weeks, QURE has shown moderate volatility, closing at $18.26 with a slight decline of $0.15, reflecting a change of approximately -0.82%. The stock has traded on robust volume, with approximately 1.37 million shares exchanged against an average volume of 3.52 million. Despite the recent decline, which places the stock approximately 76.06% below its 52-week high of $120.55, investor sentiment remains cautiously optimistic, supported by a relatively low beta of 0.773, suggesting that the stock is less volatile compared to the broader market.
The recent trading patterns illustrate a company in transition, grappling with market fluctuations while attempting to align investor expectations with its strategic objectives.
Historical Performance
A deeper dive into the company’s historical performance highlights some intriguing trends. Over the past 30 days, the stock has faced a decline of approximately 2.74%, while it has experienced a significant downturn of 61.38% over the last quarter. However, looking at a broader timeline, QURE has delivered a solid annual performance, boasting an impressive growth of 57.64% year-over-year. Weekly volatility has been recorded at 6.9%, with a slightly higher monthly volatility of 6.98%, indicating that while the stock is prone to short-term fluctuations, it has been resilient over the long haul.
The average volume over the last 10 days at 11.81 million shares—significantly higher than the quarterly average—further illustrates active trading and investor engagement with the stock.
Earnings Analysis
In its latest earnings report released on November 10, 2025, uniQure reported an actual earnings per share (EPS) of -$1.376, falling short of expectations which were estimated at -$0.85. This discrepancy resulted in a surprise factor of approximately 61.9%, indicating that the earnings report did not meet investor or analyst expectations. In the preceding report on July 29, 2025, the company had also missed estimates, delivering an actual EPS of -$0.69 against a forecast of -$0.89, but with a much smaller surprise factor of -22.47%. The current miss may raise concerns about the company’s operational challenges and impact investor confidence, though the overall growth in previous quarters may suggest potential for recovery.
Consensus Ratings
The sentiment within the analyst community appears encouraging, with a total of 12 ratings for QURE issued, consisting of 7 ‘Buy’ ratings and 5 ‘Hold’ ratings, with no ‘Sell’ recommendations. The average price target stands at $47.5, with a range that reflects significant upside—with analysts offering targets as low as $31 and as high as $70. This distribution of ratings suggests that there is a consensus that while current performance has been mixed, the longer-term potential could justify a more favorable assessment as the company navigates through its current challenges.
Stock Grading or Fundamental View
The Stocks Telegraph Score for uniQure N.V. currently sits at 39, reflecting a nuanced investment profile that indicates room for improvement in terms of overall health as well as financial performance. This score combines various financial metrics and market analyses, suggesting that while the company has promising aspects, it also faces significant hurdles that could impact its future trajectory.
Conclusion
For investors considering uniQure N.V. (QURE), the stock presents an interesting proposition, particularly for those looking for long-term growth opportunities in the biotechnology sector. While the recent rating upgrade and substantial price target indicate potential upside, prospective buyers should remain cautious of recent earnings misses and market volatility. This stock may appeal to growth-oriented investors willing to weather short-term fluctuations in exchange for potential long-term gains. However, careful analysis of the company’s strategy and market position remains essential for anyone looking to add QURE to their portfolio amid emerging risks and competitive pressures.